Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
JACC · 2025-12 · 86 (23) · 2352-2367
DOI: 10.1016/j.jacc.2025.08.040 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift JACC, 2025-12. Verfasst von Raffaele Piccolo und 38 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy, "Federico II" University Hospital, Naples, Italy. Hauptthemen laut MEDLINE: Dual Anti-Platelet Therapy, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Precision Medicine. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II.
Abstract (Originalsprache)
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended for patients undergoing percutaneous coronary intervention (PCI), although its optimal duration remains uncertain. OBJECTIVES: The authors performed a randomized trial comparing a personalized duration of DAPT, based on a risk score, for 3, 6, or 24 months with a standard duration of DAPT for 12 months after PCI. METHODS: We randomly assigned 2,107 patients undergoing PCI to receive either a personalized or a standard DAPT. The primary endpoint was a net adverse clinical event (NACE) at 24 months, defined as the composite of all-cause death, myocardial infarction, stroke, urgent target vessel revascularization, or type 2, 3, or 5 bleeding according to the Bleeding Academic Research Consortium criteria. RESULTS: At 24 months, NACE occurred in 196 of 1,055 patients (18.6%) in the personalized DAPT group and in 232 of 1,052 patients (22.2%) in the standard DAPT group (difference, 3.54 percentage points; 95% CI: -6.99 to -0.99; P = 0.040). This difference was mainly related to decreased rates of myocardial infarction (difference, -2.29 percentage points; 95% CI: -4.43 to -0.14) and urgent target vessel revascularization (difference, -1.30 percentage points; 95% CI: -2.55 to -0.05). Bleeding occurred at similar rates between the 2 groups (difference, -0.41 percentage points; 95% CI: -2.92 to 2.10). CONCLUSIONS: In patients undergoing PCI, a personalized DAPT duration from 3 to 24 months based on a clinical risk score led to a lowered risk of NACE than standard care consisting of 12 months of DAPT. (Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES [PARTHENOPE]; NCT04135989).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy, "Federico II" University Hospital, Naples, Italy.
- Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy; Division of Cardiology, A.O.R.N. "Sant'Anna e San Sebastiano", Caserta, Italy.
- Advice Pharma Group, Milan, Italy.
- P.O.S. Anna e SS. Madonna della Neve di Boscotrecase, Ospedali Riuniti Area Vesuviana, Naples, Italy.
- Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, Salerno, Italy.
- Division of Cardiology, "San Giuliano" Hospital of Giugliano in Campania, ASL Napoli2 Nord, Giugliano in Campania, Italy.
Förderung
- Dipartimento di Scienze Biomediche Avanzate, Università degli Studi di Napoli Federico II
Zitieren
APA
Piccolo, R., Calabrò, P., Carrara, G., Simonetti, F., Varricchio, A., Attisano, T., Napolitano, G., De Simone, C., Carpinella, G., Stabile, E., Cirillo, P., Di Serafino, L., Caiazzo, G., Tesorio, T., Boccalatte, M., Tuccillo, B., Avvedimento, M., Leone, A., Galasso, G., …, & PARTHENOPE Study Group (2025). Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC, 86(23), 2352-2367. https://doi.org/10.1016/j.jacc.2025.08.040
Vancouver
Piccolo R, Calabrò P, Carrara G, Simonetti F, Varricchio A, Attisano T, et al. Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC. 2025;86(23):2352-2367. doi:10.1016/j.jacc.2025.08.040
BibTeX
@article{Piccolo2025,
author = {Piccolo, Raffaele and Calabrò, Paolo and Carrara, Greta and Simonetti, Fiorenzo and Varricchio, Attilio and Attisano, Tiziana and Napolitano, Giovanni and De Simone, Ciro and Carpinella, Gerardo and Stabile, Eugenio and Cirillo, Plinio and Di Serafino, Luigi and Caiazzo, Gianluca and Tesorio, Tullio and Boccalatte, Marco and Tuccillo, Bernardino and Avvedimento, Marisa and Leone, Attilio and Galasso, Gennaro and Cesaro, Arturo and Perrotta, Rocco and Niglio, Tullio and Castiello, Domenico Simone and Immobile Molaro, Maddalena and Bardi, Luca and Spinelli, Alessandra and Cristiano, Stefano and Bellino, Michele and Leonardi, Sergio and Biscaglia, Simone and Costa, Francesco and Cassese, Salvatore and McFadden, Eugene and Heg, Dik and Stefanini, Giulio G and Franzone, Anna and Capodanno, Davide and Esposito, Giovanni and PARTHENOPE Study Group, PARTHENOPE Study Group},
title = {Personalized or Standard Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention},
journal = {JACC},
year = {2025},
volume = {86},
number = {23},
pages = {2352--2367},
doi = {10.1016/j.jacc.2025.08.040}
}
EUVIMED